The utility and efficacy of the new insulins in the management of diabetes and pregnancy.
The quest for tight glucose control has led to the development of insulin analogues (insulin lispro, insulin aspart, insulin glargine) designed to optimize glucose control while minimizing the impact of insulin therapy on daily life. Women with diabetes are increasingly likely to become pregnant on these new products and to benefit from their use while pregnant. Caution over the use of new medications in pregnancy has limited experience, but increasing evidence is emerging that use of insulin lispro is not associated with excess risk of fetal malformations, is associated with similar or better outcomes during pregnancy, and is preferred over regular insulin. Similar evidence for the other insulin analogues has yet to emerge, but is unlikely to be dissimilar.
Simmons
David
D
Department of Rural Health, Faculty Medicine Dentistry and Health Sciences, University of Melbourne, PO Box 6500, Shepparton, Victoria 3632, Australia. dsimmons@unimelb.edu.au
D000014:Abnormalities, Drug-Induced; D000906:Antibodies / Q000276:immunology; D000917:Antibody Formation; D005260:Female; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000276:immunology; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D000906:Antibodies; D007328:Insulin